76 related articles for article (PubMed ID: 29029540)
1. Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine / gemcitabine-based chemotherapy.
Chen Y; Shi Y; Yan H; Wang YR; Dai GH
Oncotarget; 2017 Sep; 8(39):66593-66600. PubMed ID: 29029540
[TBL] [Abstract][Full Text] [Related]
2. Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patients.
Chen Y; Wang Y; Shi Y; Dai G
BMC Cancer; 2017 Apr; 17(1):242. PubMed ID: 28376763
[TBL] [Abstract][Full Text] [Related]
3. Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with advanced gastric cancer undergoing first-line chemotherapy with oxaliplatin and capecitabine: a retrospective study.
Wang Y; Chen Y; Yin H; Gu X; Shi Y; Dai G
Cancer Med; 2018 Apr; 7(4):997-1005. PubMed ID: 29532995
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine.
Otake A; Tsuji D; Taku K; Kawasaki Y; Yokoi M; Nakamori H; Osada M; Matsumoto M; Inoue K; Hirai K; Itoh K
Eur J Clin Pharmacol; 2017 Aug; 73(8):1033-1039. PubMed ID: 28487999
[TBL] [Abstract][Full Text] [Related]
5. Early-onset neutropenia during perioperative chemotherapy is predictive of increased survival in patients with completely resected non-small cell lung cancer: a retrospective analysis.
Lee CY; Park SY; Shin TR; Park YB; Kim CH; Jang SH; Lee JW
Anticancer Res; 2013 Jun; 33(6):2755-61. PubMed ID: 23749937
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of chemotherapy-induced neutropenia in metastatic colon cancer patients undergoing first-line chemotherapy with FOLFOX].
Chen Y; Wang YR; Shi Y; Dai GH
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):669-674. PubMed ID: 28816286
[TBL] [Abstract][Full Text] [Related]
7. Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen.
Liu R; Huang M; Zhao X; Peng W; Sun S; Cao J; Ji D; Wang C; Guo W; Li J; Yin J; Zhu X
Oncotarget; 2015 Nov; 6(36):39018-27. PubMed ID: 26528696
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
Kasi PM; Kotani D; Cecchini M; Shitara K; Ohtsu A; Ramanathan RK; Hochster HS; Grothey A; Yoshino T
BMC Cancer; 2016 Jul; 16():467. PubMed ID: 27412464
[TBL] [Abstract][Full Text] [Related]
9. Survival analysis of 272 patients with pancreatic cancer undergoing combined treatment.
Cao N; Zhao A; Zhao G; Wang X; Han B; Lin R; Zhao Y; Yang J
Integr Cancer Ther; 2015 Mar; 14(2):133-9. PubMed ID: 25567328
[TBL] [Abstract][Full Text] [Related]
10. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer.
Ma RM; Chen CZ; Zhang W; You J; Huang DP; Guo GL
Medicine (Baltimore); 2016 Mar; 95(13):e3240. PubMed ID: 27043697
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
14. Incidence of chemotherapy-induced neutropenia in HIV-infected and uninfected patients with breast cancer receiving neoadjuvant chemotherapy.
Ngidi S; Magula N; Sartorius B; Govender P; Madiba TE
S Afr Med J; 2017 Jun; 107(7):595-601. PubMed ID: 29025449
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group.
Tewari KS; Java JJ; Gatcliffe TA; Bookman MA; Monk BJ
Gynecol Oncol; 2014 Jun; 133(3):439-45. PubMed ID: 24657300
[TBL] [Abstract][Full Text] [Related]
16. 1-Pamitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol May Reduce Incidence of Gemcitabine-Induced Neutropenia: A Pilot Case-Controlled Study.
Oh D; Kim MH; Song TJ; Cho CJ; Nam K; Cho MK; Chun JH; Jung K; Kim KP; Kim JW
World J Oncol; 2015 Aug; 6(4):410-415. PubMed ID: 28983339
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology).
İnal A; Kos FT; Algın E; Yıldız R; Berk V; Unek İT; Colak D; Dane F; Geredeli C; Isıkdogan A
Contemp Oncol (Pozn); 2015; 19(2):125-9. PubMed ID: 26034390
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model.
Chang CF; Huang PW; Chen JS; Chen YY; Lu CH; Chang PH; Hung YS; Chou WC
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30634387
[TBL] [Abstract][Full Text] [Related]
19. Effect of the timing of discontinuation of last-line chemotherapy on patient prognosis in advanced and recurrent gastric cancer.
Kimura M; Kawachi S; Go M; Iwai M; Usami E; Teramachi H; Yoshimura T
Mol Clin Oncol; 2019 Jan; 10(1):173-179. PubMed ID: 30655994
[TBL] [Abstract][Full Text] [Related]
20. Quantified CIN Score From Cell-free DNA as a Novel Noninvasive Predictor of Survival in Patients With Spinal Metastasis.
Chen S; Yang M; Zhong N; Yu D; Jian J; Jiang D; Xiao Y; Wei W; Wang T; Lou Y; Zhou Z; Xu W; Wan W; Wu Z; Wei H; Liu T; Zhao J; Yang X; Xiao J
Front Cell Dev Biol; 2021; 9():767340. PubMed ID: 34957099
[No Abstract] [Full Text] [Related]
[Next] [New Search]
